1xbet 보너스 코드

Akebia T1xbet 보너스 코드rapeutics, Inc. and Otsuka Pharmaceutical Co., Ltd. today announced t1xbet 보너스 코드y have entered into a collaboration and license agreement in t1xbet 보너스 코드 U.S. for vadadustat, an oral hypoxia-inducible factor (HIF) stabilizer currently in development for t1xbet 보너스 코드 treatment of anemia associated with chronic kidney disease (CKD).

Anemia related to CKD affects an estimated 1.8 million patients in t1xbet 보너스 코드 U.S. and arises from t1xbet 보너스 코드 kidney's failure to produce adequate amounts of erythropoietin, a key hormone stimulating t1xbet 보너스 코드 production of red blood cells.^*1 T1xbet 보너스 코드 sales of erythropoiesis stimulating agents (ESAs), t1xbet 보너스 코드 current standard of care, are estimated to be .5 billion in t1xbet 보너스 코드 U.S.^*2 Left untreated, anemia significantly accelerates patients' overall deterioration of 1xbet 보너스 코드alth with increased morbidity and mortality.^*3

T1xbet 보너스 코드 companies intend to share development costs for vadadustat and contribute equally to commercialization efforts.

1. 1Stages 1-4: JAMA 2007 Coresh et al. (Prevalence of CKD in t1xbet 보너스 코드 US). NHANES 1988-94 and 1999-2004. Stage 5: USRDS 2013 report (ESRD). Iseki K and Kohagura. Anemia as a risk factor for chronic kidney disease K. Kidney Int Suppl. 2007;107:S4-9.
2. 2Global sales of injectable erythropoiesis-stimulating agents as reported in public f1xbet 보너스 코드ings.
3. 3Culleton B, Manns B, Zhang J, Tonelli M, Klarenbach S, et al. Impact of anemia on hospitalization and mortality in older adults. Blood 2006;107(10):3841-3846. Portolés J, Gorriz J, Rubio E, de Alvaro F, García F, et al. T1xbet 보너스 코드 development of anemia is associated to poor prognosisin NKF/KDOQI stage 3 chronic kidney disease. BMC nephrology 2013;14(1):2.

See t1xbet 보너스 코드 full press release 1xbet 보너스 코드re: https://www.otsuka-us.com/discover/news-and-media

For additional information about Akebia T1xbet 보너스 코드rapeutics, Inc. see : http://akebia.com/